Back to Search
HENRY BONE, M.D.
M.D.
Endocrinology, Diabetes & Metabolism Physician
NPI: 1598760688IndividualAccepts Medicare
Specialties, Licenses & Credentials
Endocrinology, Diabetes & Metabolism PhysicianPrimary
Internal Medicine — Endocrinology, Diabetes & Metabolism
Code: 207RE0101X
43010582239(MI)
Education
UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE
Class of 1972
Research & Publications (20)
Effects of denosumab on bone mineral density and bone turnover in postmenopausal women.
PMID 18381571·J Clin Endocrinol Metab·2008
3-trial
Effects of atorvastatin on bone in postmenopausal women with dyslipidemia: a double-blind, placebo-controlled, dose-ranging trial.
PMID 17726081·J Clin Endocrinol Metab·2007
4-observational
Intravenous bisphosphonate therapy for osteoporosis: where do we stand?
PMID 16036079·Curr Osteoporos Rep·2004
4-observational
Ten years' experience with alendronate for osteoporosis in postmenopausal women.
PMID 15028823·N Engl J Med·2004
3-trial
Weekly administration of alendronate: rationale and plan for clinical assessment.
PMID 10688387·Clin Ther·2000
6-review
Alendronate and estrogen effects in postmenopausal women with low bone mineral density. Alendronate/Estrogen Study Group.
PMID 10690882·J Clin Endocrinol Metab·2000
3-trial
Modulation of B lymphocyte signalling by the B subunit of Escherichia coli heat-labile enterotoxin.
PMID 12039916·Int Immunol·2002
7-preclinical
Antigen-receptor cross-linking and lipopolysaccharide trigger distinct phosphoinositide 3-kinase-dependent pathways to NF-kappa B activation in primary B cells.
PMID 11369709·Int Immunol·2001
7-preclinical
Effects of denosumab on bone mineral density and bone turnover in postmenopausal women transitioning from alendronate therapy.
PMID 19594293·J Bone Miner Res·2010
3-trial
Preference and satisfaction with a 6-month subcutaneous injection versus a weekly tablet for treatment of low bone mass.
PMID 19657689·Osteoporos Int·2010
3-trial
Comparison of the effect of denosumab and alendronate on BMD and biochemical markers of bone turnover in postmenopausal women with low bone mass: a randomized, blinded, phase 3 trial.
PMID 18767928·J Bone Miner Res·2009
3-trial
Involvement of GSK-3 in regulation of murine embryonic stem cell self-renewal revealed by a series of bisindolylmaleimides.
PMID 19171302·Chem Biol·2009
7-preclinical
Effect of denosumab on bone mineral density in women receiving adjuvant aromatase inhibitors for non-metastatic breast cancer: subgroup analyses of a phase 3 study.
PMID 19308727·Breast Cancer Res Treat·2009
3-trial
Four-month treatment with GLP-2 significantly increases hip BMD: a randomized, placebo-controlled, dose-ranging study in postmenopausal women with low BMD.
PMID 19631303·Bone·2009
2-rct
Adherence to and gastrointestinal tolerability of monthly oral or quarterly intravenous ibandronate therapy in women with previous intolerance to oral bisphosphonates: a 12-month, open-label, prospective evaluation.
PMID 18498910·Clin Ther·2008
3-trial
Somatostatin infusion increases intestinal ischemia and does not improve vasoconstrictor response to norepinephrine in ovine endotoxemia.
PMID 18391853·Shock·2008
7-preclinical
Randomized trial of denosumab in patients receiving adjuvant aromatase inhibitors for nonmetastatic breast cancer.
PMID 18725648·J Clin Oncol·2008
3-trial
Sequestosome 1 (SQSTM1) mutations in Paget's disease of bone from the United States.
PMID 18379713·Calcif Tissue Int·2008
8-other
Data courtesy of the U.S. National Library of Medicine (NLM). Ltrl is not affiliated with or endorsed by NLM.
Contact & Hours
- Address
- 22201 MOROSS RD, SUITE 260
DETROIT, MI 48236 - Phone
- (313) 640-7700
Quick Facts
- NPI
- 1598760688
- Entity Type
- Individual
- Gender
- Male
- Medicare
- Accepted
- Specialties
- 1
- Locations
- 1
- Years in Practice
- 54
- Publications
- 20
Are you this provider?
Claim Your Profile